Medicine 3.0: The Longevity Framework Explained
A framework rather than a protocol, and the most useful conceptual contribution in popular longevity writing. Its four disease targets, its emphasis on physical capacity, and where it is harder to apply than it reads.
The Short Answer
Peter Attia's Medicine 3.0 is a framework for how to think about long-term health rather than a list of things to take, which is what makes it more durable than most popular longevity content. Its central claims are that medicine should act decades before disease presents, that the four conditions responsible for most deaths in developed countries should be addressed simultaneously rather than sequentially, and that physical capacity in the final decade of life is a legitimate planning target. Two of those three are uncontroversial among clinicians and underpractised.
The Three Medicines
The framework's organising device is a progression.
Medicine 1.0 was pre-scientific: observation, humoral theory, remedies without mechanism.
Medicine 2.0 is the current standard, built on germ theory, randomised trials and pharmaceutical intervention. It is extraordinarily good at acute illness and infectious disease, and it is organised to act once disease has presented and can be identified.
Medicine 3.0 proposes acting on trajectory rather than on presented disease: risk assessed and addressed decades early, tolerance for intervention before a threshold is crossed, healthspan as the endpoint alongside lifespan, and the patient as an active participant rather than a recipient.
The critique implied here is structural rather than a complaint about clinicians. Medical systems are organised around presentation, reimbursement follows a coded condition, and guidelines are written for populations at threshold. A person who wants their arterial disease addressed at 35 rather than 60 is asking the system to do something it is not configured to do.
The Four Targets
The framework identifies four disease groups responsible for the great majority of deaths in developed countries and argues that all four should be addressed concurrently, since they share risk factors and their decades-long preclinical phases overlap.
Atherosclerotic cardiovascular disease. The framework's emphasis on apolipoprotein B rather than LDL cholesterol as the causal exposure is well grounded, as is its emphasis on lipoprotein(a) measurement, which is inherited, largely unmodifiable by lifestyle and commonly not measured.
Cancer. Emphasis on screening earlier and more thoroughly than standard guidelines recommend. This is where the framework is most contested, because earlier and broader screening carries real costs in false positives, over-detection and downstream procedures, and guideline thresholds exist partly to manage those costs.
Neurodegenerative disease. Emphasis on the long preclinical phase, on cardiovascular and metabolic contributions to brain health, and on genetic context including APOE status.
Metabolic dysfunction. Placed upstream of the other three rather than as a fourth parallel item, which matches the mechanistic picture well. Insulin resistance, visceral adiposity and hepatic fat accumulation precede and contribute to all of the above.
Grouping metabolic dysfunction as the upstream driver is the framework's sharpest analytical move, and it aligns closely with a Pillar-based view of the body.
Physical Capacity as a Planning Target
The most practically useful element is the idea of working backward from the function you want in your final decade, then determining what capacity you need now to still have it then.
The reasoning is straightforward. Muscle mass and strength decline from midlife at a rate that accelerates with age. VO2 max declines by roughly 10 per cent per decade after the thirties, faster if untrained. A person who wants to carry a bag up stairs, get off the floor unassisted or hike at 85 needs a substantial reserve at 50, because they will lose much of it in the interval.
This inverts the usual framing. Rather than training for current performance, you train to protect a floor decades out. It also explains why the framework uses grip strength, VO2 max, and specific capacities like carrying and stability as primary metrics, and why it emphasises stability and fall prevention, since a hip fracture in later decades carries mortality risk comparable to a serious disease.
The supporting evidence here is strong. Cardiorespiratory fitness and muscle strength are among the most robust predictors of all-cause mortality in prospective data, with effect sizes larger than most of what supplements attempt to influence.
Where the Framework Is Harder Than It Reads
| Element | Difficulty in practice |
|---|---|
| Aggressive early screening | False positives, over-detection and procedural risk are real and accumulate |
| Extensive testing | Cost and access; much of it is outside standard reimbursement |
| Early pharmacological intervention | Requires a clinician willing to prescribe below guideline thresholds |
| Time requirement | The exercise prescription alone is substantial weekly hours |
| Evidence base for early action | Trials generally enrol people at threshold, so extrapolating downward is inference |
| Individual risk estimation | Population risk models are weak at the individual level |
The screening tension deserves to be stated plainly rather than waved past. Detecting more early abnormalities is not automatically better: some would never have progressed, and investigating them carries its own morbidity. Reasonable clinicians disagree about where the line sits, and a framework that emphasises early detection inherits that disagreement rather than resolving it.
What Transfers Without a Concierge Practice
The framework is often delivered alongside a level of testing and clinical access most people do not have. Stripped to what is generally available:
Measure apolipoprotein B and lipoprotein(a) once. ApoB is a better exposure measure than LDL cholesterol, and Lp(a) is inherited, so a single measurement is usually sufficient and it is commonly omitted from standard panels.
Take metabolic markers seriously early. Fasting insulin, HbA1c, triglyceride to HDL ratio and waist circumference identify drift years before a clinical threshold.
Train for the floor, not the peak. Resistance work, sustained aerobic volume, high-intensity intervals for VO2 max, and deliberate stability work. The last is the one everyone skips.
Know your genetic context where it changes decisions. APOE status and Lp(a) are the two most commonly cited examples.
Protect sleep. The framework places it as foundational, and the evidence supports that placement.
None of this requires a specialist practice. It requires asking for two additional tests and taking the training prescription seriously, which is a modest ask relative to the framework's reputation for intensity.
Its Real Contribution
Medicine 3.0's value is that it gives people a structure for thinking about a forty-year time horizon, which is otherwise very difficult to reason about. It replaces "am I healthy now" with "what trajectory am I on", and that reframing does more work than any individual recommendation inside it.
It is also, notably, not a supplement framework. Compounds appear as a minor and heavily caveated element, well below exercise, sleep, nutrition, metabolic health and targeted early intervention. Popular longevity content inverts that ordering almost universally, and the framework's refusal to do so is part of why it has held up.
The right way to use it is as a set of questions rather than a protocol: which of the four am I most exposed to, what is my metabolic trajectory, and what capacity will I need in thirty years that I am not building now.
The AEONNN Perspective
Medicine 3.0 and AEONNN's architecture arrive at similar structures from different directions. The framework's insistence that metabolic dysfunction sits upstream of the other three targets is essentially a statement about system interdependence, which is what the Pillar Matrix encodes: Pillar 4 influences Pillar 5 and Pillar 3, and modelling them as independent misses the mechanism.
Its emphasis on physical capacity as a planning target maps directly to Pillar 7, Structural and Musculoskeletal Support, and the Real-Time User layer is where capacity is actually observed between measurements. The Consensus layer records where the framework departs from guideline positions, particularly on screening intensity, and the platform presents that as a genuine disagreement rather than settled practice.
The framework's ordering, behaviour and early detection well above compounds, is also AEONNN's. A platform whose output is a supplement stack has an obvious incentive to invert that, and the Insight Protocol is built to resist it: where sleep, training or metabolic drift is the dominant signal, that is what the platform surfaces.
Pillar Matrix mapping
Longevity and Biological Age, Metabolic and Cardiovascular Health, Structural and Musculoskeletal Support
Database Matrix layers
- Meta / Consensus Layer (JAMA, BMJ, specialty society positions)
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Population Layer (UK Biobank, NHANES)
- Real-Time User Layer (wearable and adherence signals)
Frequently Asked
What is Medicine 3.0?
Peter Attia’s framework proposing that medicine should act on trajectory decades before disease presents, address the four major causes of death concurrently, and hold healthspan and physical capacity as endpoints alongside lifespan.
What are the four horsemen?
Atherosclerotic cardiovascular disease, cancer, neurodegenerative disease and metabolic dysfunction, with metabolic dysfunction framed as upstream of the other three rather than parallel to them.
Why apolipoprotein B rather than LDL cholesterol?
ApoB counts the atherogenic particles themselves rather than the cholesterol they carry, which makes it a more direct measure of the causal exposure. It is commonly absent from standard panels.
What is the criticism of the framework?
Mainly its screening intensity. Detecting more early abnormalities carries false positives, over-detection and procedural risk, and trials generally enrol people at guideline threshold, so acting far below it is inference.
What does training for the final decade mean?
Working backward from the physical function you want at 85 to the capacity you need now, because strength and VO2 max decline substantially in the interval. Stability and fall prevention are part of it.
Do I need a concierge practice to use it?
No. The generally available core is measuring apolipoprotein B and lipoprotein(a) once, taking metabolic markers seriously early, training across strength, aerobic capacity and stability, and protecting sleep.
Where do supplements sit in the framework?
Well below exercise, sleep, nutrition, metabolic health and early detection. Compounds appear as a minor and heavily caveated element, which is the reverse of most popular longevity content.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.